Patents by Inventor Paul Alan Glossop

Paul Alan Glossop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxaborole analogs and uses thereof
    Patent number: 11691992
    Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: July 4, 2023
    Assignees: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretary of the Army
    Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
  • HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS
    Publication number: 20230036854
    Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, R4, R5, R6, R7, R8, R9, R10, Z, X1, X2, X3, L2, HET, n and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
    Type: Application
    Filed: November 15, 2019
    Publication date: February 2, 2023
    Inventors: Gareth RICHARDS, Timothy M. SKERRY, Joseph P.A. HARRITY, Jean-Olivier ZIRIMWABAGABO, Matthew J. TOZER, Karl Richard GIBSON, Roderick Alan PORTER, Paul Alan GLOSSOP
  • Compounds
    Patent number: 11400081
    Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: August 2, 2022
    Assignee: The University of Sheffield
    Inventors: Gareth Richards, Timothy M. Skerry, Joseph P. A. Harrity, Jean-Olivier Zirimwabagabo, Matthew J. Tozer, Karl Richard Gibson, Roderick Alan Porter, Paul Matthew Blaney, Paul Alan Glossop
  • HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS
    Publication number: 20220023281
    Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 27, 2022
    Inventors: Gareth RICHARDS, Timothy M. SKERRY, Joseph P.A. HARRITY, Jean-Olivier ZIRIMWABAGABO, Matthew J. TOZER, Karl Richard GIBSON, Roderick Alan PORTER, Paul Alan GLOSSOP
  • NOVEL OXABOROLE ANALOGS AND USES THEREOF
    Publication number: 20210253605
    Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
    Type: Application
    Filed: February 11, 2021
    Publication date: August 19, 2021
    Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
  • COMPOUNDS
    Publication number: 20210113534
    Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
    Type: Application
    Filed: May 16, 2018
    Publication date: April 22, 2021
    Inventors: Gareth Richards, Timothy M. Skerry, Joseph P.A. Harrity, Jean-Olivier Zirimwabagabo, Matthew J. Tozer, Karl Richard Gibson, Roderick Alan Porter, Paul Matthew Blaney, Paul Alan Glossop
  • Oxaborole analogs and uses thereof
    Patent number: 10961261
    Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: March 30, 2021
    Assignees: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretaryof the Army
    Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
  • NOVEL OXABOROLE ANALOGS AND USES THEREOF
    Publication number: 20200024289
    Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
    Type: Application
    Filed: March 1, 2018
    Publication date: January 23, 2020
    Applicants: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretary of the Army, The Government of the United States, as represented by the Secretary of the Army
    Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
  • Pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors
    Patent number: 10065964
    Abstract: The present invention relates to compounds of formula (Ia), (Ib) or (Ic): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma, COPD, allergic rhinitis, chronic sinusitis, atopic dermatitis, psoriasis, rosacea, alopecia, allergic conjunctivitis and dry eye disease.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: September 4, 2018
    Assignee: Ziarco Pharma Ltd.
    Inventors: Gavin A. Whitlock, Paul Alan Glossop
  • 2-(2-AMINOCYCLOHEXYL)AMINO-PYRIMIDINE-5-CARBOXAMIDES AS SPLEEN TYROSINE KINASE(SYK) INHIBITORS
    Publication number: 20170145019
    Abstract: The present invention relates to compounds of formula (Ia), (Ib) or (Ic): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma, COPD, allergic rhinitis, chronic sinusitis, atopic dermatitis, psoriasis, rosacea, alopecia, allergic conjunctivitis and dry eye disease.
    Type: Application
    Filed: December 13, 2016
    Publication date: May 25, 2017
    Inventors: Gavin A. WHITLOCK, Paul Alan GLOSSOP
  • Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors
    Patent number: 9533989
    Abstract: The present invention relates to compounds of formula (Ia), (Ib) or (Ic): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma, COPD, allergic rhinitis, chronic sinusitis, atopic dermatitis, psoriasis, rosacea, alopecia, allergic conjunctivitis and dry eye disease.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: January 3, 2017
    Assignee: Ziarco Pharma Ltd.
    Inventors: Gavin A. Whitlock, Paul Alan Glossop
  • 2-(-Aminocyclohexyl)Amino-Pyrimidine-5-Carboxamides as Spleen Tyrosine Kinasei(SYK) Inhibitors
    Publication number: 20150232470
    Abstract: The present invention relates to compounds of formula (Ia), (Ib) or (Ic): to pharmaceutically acceptable salts therefore fore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma, COPD, allergic rhinitis, chronic sinusitis, atopic dermatitis, psoriasis, rosacea, alopecia, allergic conjunctivitis and dry eye disease
    Type: Application
    Filed: September 18, 2013
    Publication date: August 20, 2015
    Inventors: Gavin A. Whitlock, Paul Alan Glossop
  • NOVEL GLUCOCORTICOLD RECEPTOR AGONISTS
    Publication number: 20140336160
    Abstract: This invention relates to novel glucocorticoid receptor agonists of formula (I): and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to their combination with one or more other therapeutic agents, as well as to their use for the treatment of a number of inflammatory and allergic diseases, disorders and conditions.
    Type: Application
    Filed: July 23, 2014
    Publication date: November 13, 2014
    Inventors: Paul Alan Glossop, David Simon Millan, David Anthony Price
  • Glucocorticoid receptor agonists
    Patent number: 8822439
    Abstract: This invention relates to novel glucocorticoid receptor agonists of formula (I): and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to their combination with one or more other therapeutic agents, as well as to their use for the treatment of a number of inflammatory and allergic diseases, disorders and conditions.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: September 2, 2014
    Assignee: Pfizer Inc.
    Inventors: Paul Alan Glossop, David Simon Millan, David Anthony Price
  • Carboxamide derivatives as muscarinic receptor antagonists
    Patent number: 8486992
    Abstract: The invention relates to compounds of formula processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical composition containing them.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: July 16, 2013
    Assignee: Pfizer Limited
    Inventors: Paul Alan Glossop, Simon John Mantell, Anthony Wood, Christine Anne Louise Watson
  • Carboxamide derivatives as muscarinic receptor antagonists
    Patent number: 8268881
    Abstract: The invention relates to compounds of formula processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical composition containing them.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: September 18, 2012
    Assignee: Pfizer Limited
    Inventors: Paul Alan Glossop, Simon John Mantell, Anthony Wood, Christine Anne Louise Watson
  • Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
    Patent number: 8263583
    Abstract: This invention relates to the hydrochloride salt of 5-[3-{3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenyl-hexanamide or derived form thereof and its use as a medicament.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: September 11, 2012
    Assignee: Pfizer Limited
    Inventors: Paul Alan Glossop, Kim James
  • Nicotinamide Derivatives
    Publication number: 20110306597
    Abstract: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are defined herein, to compositions containing such compounds and to the uses of such compounds for the treatment of allergic and respiratory conditions.
    Type: Application
    Filed: June 12, 2009
    Publication date: December 15, 2011
    Inventors: James Michael Crawforth, Paul Alan Glossop, Bruce Cameron Hamper, Wei Huang, Bradley Elwood Neal, Simon John Mantell, Kirk Olson, Atli Thorarensen, Steve Ronald Turner
  • Carboxamide Derivatives As Muscarinic Receptor Antagonists
    Publication number: 20110251164
    Abstract: The invention relates to compounds of formula processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical composition containing them.
    Type: Application
    Filed: July 1, 2010
    Publication date: October 13, 2011
    Inventors: Paul Alan Glossop, Simon John Mantell, Anthony Wood, Christine Anne Louise Watson
  • Sulfonamide derivatives for the treatment of diseases
    Patent number: 8013019
    Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: September 6, 2011
    Assignee: Pfizer Inc
    Inventors: Alan Daniel Brown, Mark Edward Bunnage, Paul Alan Glossop, Kim James, Charlotte Alice Louise Lane, Russel Andrew Lewthwaite, Ian Brian Moses, David Anthony Price, Nicholas Murray Thomson